```markdown
---
nda: 210852
product: "Cyclophosphamide Injection, 500 mg/mL, 1 g/2mL, 2 g/4mL"
submission_type: "505(b)(2)"
sponsor:
  name: "Dr. Reddy’s Laboratories Limited"
  address:
    - "c/o Dr. Reddy’s Laboratories, Inc."
    - "107 College Road East"
    - "Princeton, NJ 08540"
fda_contacts:
  primary_contact:
    name: "Fatima Rizvi, PharmD"
    title: "Regulatory Project Manager"
    phone: "(240) 402-7426"
    email: "Fatima.Rizvi@fda.hhs.gov"
signatories:
  - name: "Amna Ibrahim, MD"
    title: "Deputy Director"
    division: "Division of Oncology 1"
    office: "Office of Oncologic Diseases"
    center: "Center for Drug Evaluation and Research"
  - name: "Laleh Amiri-Kordestani, MD"
    title: "Director"
    division: "Division of Oncology 1"
    office: "Office of Oncologic Diseases"
    center: "Center for Drug Evaluation and Research"
approval_status: "Not approved—complete response issued"
facility_inspection: "Deficiencies found—approval pending resolution"
---

## Critical Data

| Field                     | Value                                                                 |
|---------------------------|-----------------------------------------------------------------------|
| NDA Number                | 210852                                                                |
| Product Name              | Cyclophosphamide Injection                                            |
| Strengths                 | 500 mg/mL, 1 g/2mL, 2 g/4mL                                            |
| Submission Type           | 505(b)(2)                                                             |
| Sponsor                   | Dr. Reddy’s Laboratories Limited                                      |
| Sponsor Address           | 107 College Road East, Princeton, NJ 08540                           |
| Manufacturing Site        | [FEI redacted] (deficiencies identified)                              |
| Approval Status           | Not approved (Complete Response Letter issued)                        |
| FDA Contact               | Fatima Rizvi, PharmD – Regulatory Project Manager                     |
| Contact Phone             | (240) 402-7426                                                        |
| Contact Email             | Fatima.Rizvi@fda.hhs.gov                                              |
| Letter Signatories        | Amna Ibrahim, MD & Laleh Amiri-Kordestani, MD                         |

---

# COMPLETE RESPONSE – NDA 210852

**Sponsor:**  
Dr. Reddy’s Laboratories Limited  
c/o Dr. Reddy’s Laboratories, Inc.  
107 College Road East  
Princeton, NJ 08540  

---

## APPLICATION INFORMATION

- NDA: 210852
- Product: Cyclophosphamide Injection, 500 mg/mL, 1 g/2mL, 2 g/4mL
- Submission Type: 505(b)(2)

---

## FACILITY INSPECTIONS

During a recent inspection of the manufacturing facility [FEI redacted], our field investigator observed deficiencies. Satisfactory resolution of these deficiencies is required before this application may be approved.

---

## PRESCRIBING INFORMATION

Your proposed Prescribing Information must conform to content and format regulations at:

- 21 CFR 201.56(a) and (d)
- 21 CFR 201.57

We encourage you to review labeling resources at:

- [Prescription Drug Labeling Resources](https://www.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources)
- [Pregnancy and Lactation Labeling Final Rule](https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs-final-rule)

Key tools and guidance include:

- Final Rules on PI content and format
- SRPI (Selected Requirements for Prescribing Information) checklist
- FDA’s established pharmacologic class text phrases

You must submit:

- Revised labeling using a clean and annotated Microsoft Word version
- Updated content of labeling per 21 CFR 314.50(l)(1)(i) in SPL format:  
  [Structured Product Labeling Resources](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm)

---

## CARTON AND CONTAINER LABELING

Submit revised draft carton and container labeling based on FDA recommendations. FDA reserves further comment until the application is otherwise adequate.

---

## SAFETY UPDATE

When responding to the deficiencies, include a safety update per 21 CFR 314.50(d)(5)(vi)(b). This must include data from all nonclinical and clinical studies/trials regardless of indication, dosage form, or dose level.

### Required safety content:

1. Describe any significant changes or findings in the safety profile.
2. For discontinuations due to adverse events, serious and common adverse events:
   - Present new safety data using the same format as original submission
   - Tabulate combined original and new data
   - Include comparison tables between original and new adverse event frequencies
   - For other indications, provide separate tables of adverse events
3. Retabulate reasons for premature trial discontinuation and describe trends or patterns
4. Provide:
   - Case report forms for any trial deaths or discontinuations due to adverse events
   - Narrative summaries for serious adverse events
5. Describe any changes in incidence of less serious, common adverse events
6. Provide updated exposure data (e.g., number of subjects, person-time)
7. Summarize worldwide experience on drug safety, with updated foreign market usage estimate
8. Provide English translations of any current approved foreign labeling not previously submitted

---

## OTHER

Within one year of the date on this letter, you are required to:

- Resubmit the application fully addressing all deficiencies
- Or take another regulatory action under 21 CFR 314.110
- Or request a withdrawal per 21 CFR 314.65

You may also request an extension of time to resubmit.

### Requirements for resubmission:

- Clearly mark with "**RESUBMISSION**" in **large bold font** on the cover letter
- Cover letter must state it is a complete response to this CR letter
- Partial responses will not start a new review cycle

---

## MEETING REQUESTS

You may request a meeting or teleconference with FDA to discuss actions needed for approval. Submit meeting requests per:

- [Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products](https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/guidances/ucm590547)

---

The drug product **may not be legally marketed** until written approval is received.

---

## FDA CONTACTS

**Primary Contact:**  
Fatima Rizvi, PharmD  
Regulatory Project Manager  
Phone: (240) 402-7426  
Email: Fatima.Rizvi@fda.hhs.gov

---

## SIGNATORIES

Amna Ibrahim, MD  
Deputy Director  
Division of Oncology 1  
Office of Oncologic Diseases  
Center for Drug Evaluation and Research

Laleh Amiri-Kordestani, MD  
Director  
Division of Oncology 1  
Office of Oncologic Diseases  
Center for Drug Evaluation and Research

---

> Portions of this letter have been redacted in accordance with (b)(4).
```